Los Angeles, California 90095

  • Kidney Cancer


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of pentostatin followed by peripheral stem cell transplantation in treating patients who have advanced kidney cancer.

Study summary:

OBJECTIVES: - Determine the duration and efficiency of hematopoietic and immunologic engraftment in patients with advanced renal cell carcinoma treated with pentostatin followed by related allogeneic stem cell transplantation. - Determine the hematologic and non-hematologic toxic effects of this regimen in these patients. - Determine the incidence and severity of graft-versus-host disease in patients treated with this regimen. OUTLINE: This is a dose-escalation study of pentostatin. - Phase I: Patients receive pentostatin IV on days -7, -5, and -3 followed by allogeneic stem cell transplantation on day 0. Beginning on day 1, patients receive filgrastim (G-CSF) IV over 1 hour or subcutaneously daily until blood counts recover. As graft-versus-host disease prophylaxis, patients receive cyclosporine IV continuously until stem cell engraftment and then orally with gradual tapering. Cohorts of 3 to 6 patients receive escalating doses of pentostatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity. - Phase II: Patients receive treatment as in phase I at the MTD for pentostatin. Patients are followed weekly for 60 days and then monthly for 10 months. PROJECTED ACCRUAL: A total of 24 patients (12 per phase) will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically confirmed advanced renal cell cancer - No bone metastases - No CNS disease - Must have an allogeneic donor available PATIENT CHARACTERISTICS: Age: - Over 18 Performance status: - ECOG 0-1 Life expectancy: - 3 to 6 months Hematopoietic: - Hemoglobin at least 10 g/dL - Complete blood count normal Hepatic: - Bilirubin no greater than 3 times upper limit of normal (ULN) - Transaminases no greater than 4 times ULN - No evidence of portal hypertension Renal: - Creatinine no greater than 2.0 mg/dL - No uncontrolled hypercalcemia Cardiovascular: - No New York Heart Association class 3 or 4 heart disease Pulmonary: - DLCO at least 40% of predicted Other: - No severe functional neurological impairment - HIV negative - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - No more than 1 prior biologic therapy Chemotherapy: - No more than 6 months of prior chemotherapy Endocrine therapy: - At least 1 year since prior steroids Radiotherapy: - Not specified Surgery: - Not specified



Primary Contact:

Study Chair
Gary J. Schiller, MD
Jonsson Comprehensive Cancer Center

Backup Contact:


Location Contact:

Los Angeles, California 90095
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.